Technology

Soligenix

$1.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.69%) Today
-$0.01 (-0.70%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Soligenix and other stocks, options, and ETFs commission-free!

About SNGX

Soligenix, Inc. Common Stock, also called Soligenix, is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ. The listed name for SNGX is Soligenix, Inc. Common Stock.

CEO
Christopher J. Schaber
Employees
16
Headquarters
Princeton, New Jersey
Founded
1987
Market Cap
41.50M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.69M
High Today
$1.47
Low Today
$1.41
Open Price
$1.44
Volume
1.16M
52 Week High
$3.54
52 Week Low
$1.21

Collections

SNGX Earnings

-$0.32
-$0.21
-$0.11
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 29, Pre-Market

You May Also Like

QPX
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure